Omeros Co. (NASDAQ:OMER) Given Consensus Recommendation of “Hold” by Brokerages

Omeros Co. (NASDAQ:OMERGet Rating) has been assigned an average recommendation of “Hold” from the eight ratings firms that are covering the firm, MarketBeat.com reports. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $34.25.

OMER has been the subject of several recent research reports. StockNews.com initiated coverage on shares of Omeros in a report on Thursday, March 31st. They set a “hold” rating for the company. Zacks Investment Research downgraded shares of Omeros from a “buy” rating to a “hold” rating in a report on Wednesday, April 6th. Finally, Cantor Fitzgerald decreased their price target on shares of Omeros from $34.00 to $20.00 in a research note on Tuesday, January 18th.

Omeros stock traded up $0.07 during trading hours on Monday, reaching $4.18. 4,549 shares of the stock were exchanged, compared to its average volume of 592,766. The stock has a market cap of $262.20 million, a P/E ratio of 1.31 and a beta of 0.55. The company has a debt-to-equity ratio of 13.18, a quick ratio of 4.79 and a current ratio of 4.79. Omeros has a 52-week low of $3.90 and a 52-week high of $18.86. The firm’s 50 day moving average is $6.09 and its 200 day moving average is $6.59.

Omeros (NASDAQ:OMERGet Rating) last announced its quarterly earnings results on Tuesday, March 1st. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.30) by ($0.07). The firm had revenue of $32.92 million for the quarter, compared to analyst estimates of $31.84 million. During the same period in the previous year, the company earned ($0.54) EPS. Equities research analysts expect that Omeros will post -1.66 EPS for the current fiscal year.

Several institutional investors and hedge funds have recently bought and sold shares of the company. Sheaff Brock Investment Advisors LLC increased its stake in shares of Omeros by 3.5% in the third quarter. Sheaff Brock Investment Advisors LLC now owns 43,830 shares of the biopharmaceutical company’s stock worth $605,000 after buying an additional 1,500 shares during the last quarter. California State Teachers Retirement System increased its stake in shares of Omeros by 2.1% in the fourth quarter. California State Teachers Retirement System now owns 82,708 shares of the biopharmaceutical company’s stock worth $532,000 after buying an additional 1,672 shares during the last quarter. Swiss National Bank increased its stake in shares of Omeros by 1.4% in the third quarter. Swiss National Bank now owns 130,900 shares of the biopharmaceutical company’s stock worth $1,805,000 after buying an additional 1,800 shares during the last quarter. HighTower Advisors LLC increased its stake in shares of Omeros by 6.2% in the third quarter. HighTower Advisors LLC now owns 34,314 shares of the biopharmaceutical company’s stock worth $472,000 after buying an additional 2,000 shares during the last quarter. Finally, Creative Financial Designs Inc. ADV increased its stake in shares of Omeros by 29.6% in the fourth quarter. Creative Financial Designs Inc. ADV now owns 8,750 shares of the biopharmaceutical company’s stock worth $56,000 after buying an additional 2,000 shares during the last quarter. Institutional investors own 47.77% of the company’s stock.

Omeros Company Profile (Get Rating)

Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders.

Featured Articles

Analyst Recommendations for Omeros (NASDAQ:OMER)

Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.